~~<i id='2F5EF8E099'><strike id='2F5EF8E099'><tt id='2F5EF8E099'><pre id='2F5EF8E099'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-09-29 09:41:31 Page View：8315

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT series 'Denied by AI' wins major journalism prizes
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

focus

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

What a koala virus tells us about the human genome

ADOBEThehumangenomeisnotentirelyhuman.Some8%ofourDNA,infact,originatedinviruses,remnantsofancientsin

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

As H5N1 spreads in cows, experts warn against drinking raw milk

RobertF.Bukaty/APScientistswhoknowaboutthetypesofpathogens—E.coliandSalmonellaamongthem— thatcanbetr